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Abstract
Background: Hypertension is one of the largest health burdens in the world, leading to stroke, coronary heart
disease, myocardial infarct, peripheral artery disease (PAD) and renal failure. There are many pharmaceutical
medications on the market for blood pressure management. Many of these medications have undesirable side
effects or are expensive. Dietary intervention with omega-3 fatty acids has become a popular alternative to
medication for blood pressure (BP) control. The cardiovascular benefits of omega-3 fatty acids consumed via
fish oil have been well established. More research is being done to establish the mechanism and efficacy of
other dietary sources containing fatty acids. It has been suggested that foods high in alpha-linolenic acid
(ALA) may have cardio protective properties. Dietary flaxseed is one of the foods of interest being it contains
the highest level of ALA. Although the mechanisms are not fully understood, dietary flaxseed may be an
effective and safe alternative for BP management.
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL, and Web of Science using
the keywords: flax, flaxseed, linseed oil, blood pressure, and hypertension. Relevant articles were assessed for
quality using GRADE. A search on the NIH clinical trials site reveals there is one trial currently registered
relating to the antihypertensive effects of dietary flaxseed.
Results: Two studies met the search criteria and were included in this systematic review. The first study,
FLAX-PAD, was a double blind, placebo-controlled, randomized controlled study (RCT) utilized to examine
the effects of dietary flaxseed on systolic BP and diastolic BP in patients newly diagnosed with PAD. This
study demonstrated the antihypertensive effects in patients consuming dietary flaxseed. Researchers also
revealed the relationship between plasma ALA levels and blood pressure. The second study was a prospective,
two-group, parallel-arm design RCT to examine the effects of dietary flaxseed on blood pressure in middle-
aged dyslipidemic men. This study revealed a significant reduction in blood pressure in individuals receiving
the intervention.
Conclusion: Daily consumption of 30g of milled flaxseed or 15mL of flax oil per day has shown an
antihypertensive effect on select patient populations. The latest studies regarding flaxseed and its
antihypertensive effects seem promising, but further randomized controlled trials are needed to clearly
establish its efficacy.
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Abstract   
 
Background: Hypertension is one of the largest health burdens in the world, leading to 
stroke, coronary heart disease, myocardial infarct, peripheral artery disease (PAD) and 
renal failure. There are many pharmaceutical medications on the market for blood 
pressure management. Many of these medications have undesirable side effects or are 
expensive. Dietary intervention with omega-3 fatty acids has become a popular 
alternative to medication for blood pressure (BP) control. The cardiovascular benefits of 
omega-3 fatty acids consumed via fish oil have been well established. More research is 
being done to establish the mechanism and efficacy of other dietary sources containing 
fatty acids. It has been suggested that foods high in alpha-linolenic acid (ALA) may have 
cardio protective properties. Dietary flaxseed is one of the foods of interest being it 
contains the highest level of ALA. Although the mechanisms are not fully understood, 
dietary flaxseed may be an effective and safe alternative for BP management. 
 
Methods:  An exhaustive search was conducted using Medline-OVID, CINAHL, and 
Web of Science using the keywords: flax, flaxseed, linseed oil, blood pressure, and 
hypertension.  Relevant articles were assessed for quality using GRADE.  A search on the 
NIH clinical trials site reveals there is one trial currently registered relating to the 
antihypertensive effects of dietary flaxseed.  
 
Results:  Two studies met the search criteria and were included in this systematic review. 
The first study, FLAX-PAD, was a double blind, placebo-controlled, randomized 
controlled study (RCT) utilized to examine the effects of dietary flaxseed on systolic BP 
and diastolic BP in patients newly diagnosed with PAD. This study demonstrated the 
antihypertensive effects in patients consuming dietary flaxseed. Researchers also revealed 
the relationship between plasma ALA levels and blood pressure. The second study was a 
prospective, two-group, parallel-arm design RCT to examine the effects of dietary 
flaxseed on blood pressure in middle-aged dyslipidemic men. This study revealed a 
significant reduction in blood pressure in individuals receiving the intervention. 
 
Conclusion:  Daily consumption of 30g of milled flaxseed or 15mL of flax oil per day 
has shown an antihypertensive effect on select patient populations. The latest studies 
regarding flaxseed and its antihypertensive effects seem promising, but further 
randomized controlled trials are needed to clearly establish its efficacy. 
 
Keywords: Flaxseed, flax, linseed oil, hypertension, blood pressure. 
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Antihypertensive Effects of Dietary Flaxseed 
BACKGROUND 
 Hypertension is one of the leading causes of the global burden of disease.1 
Worldwide, 7.6 million premature deaths were attributed to high blood pressure.2 It is 
estimated that as of 2008, approximately 68 million Americans over the age of 18 had 
hypertension and of those approximately 31 million had their disease under control.3 The 
prevalence of hypertension increases with advancing age to the point where more than 
half of people 60–69 years of age and approximately three-fourths of those 70 years of 
age and older are affected.4  Hypertension is an independent risk factor for coronary heart 
disease (CHD), congestive heart failure (CHF), stroke, renal failure and peripheral artery 
disease (PAD) and is defined as a blood pressure of <140/90. There have been numerous 
studies published on the importance of blood pressure control in reducing these risks. 
There are a variety of different antihypertensive medications on the market, and many are 
expensive or have side effects that may deter an individual from taking them.  
Many people in the US and the world look to alternative therapy for treatment of 
various diseases as opposed to taking pharmaceutical medications. Dietary 
supplementation has become a popular alternate, providing people with numerous health 
benefits and reducing the risk of disease. Recent research has shown that increased levels 
of omega-3 fatty acid consumption appear to have a dose dependent hypotensive effect 
on patients who have hypertension and little to no effect on normotensive patients.5 
Generally, we consume these fatty acids through marine oils found in fish, but recently 
various nuts and seeds have been identified as containing these essential fatty acids. One 
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such dietary supplement is flaxseed and may prove to be an important addition to the 
management of hypertension.  
Flax is a blue flowered crop named Linum usitatissimum that is in the botanical 
family Linaceae. The terms flaxseed and linseed are used interchangeably in the US, 
although flaxseed is more commonly associated with the dietary supplement consumed 
by humans. Flax comes in a variety of forms ranging from whole seeds to oil. The seeds 
themselves have a chewy consistency and a nutty flavor. Flax is rich in fat, protein, and 
dietary fiber. It also contains modest amounts of amino acids, vitamins, and minerals (see 
Table I).  In Canada, the most common form of flax is brown-seeded flax. It is rich in the 
omega-3 fatty acid alpha-linolenic acid (ALA), an essential fatty acid. The US has 
developed its own form of flax called Omega, which has the same high content of ALA. 
Flax is the richest source of ALA constituting fifty-seven percent of its total fatty acids. 
Both brown and Omega flax can be purchased at grocery stores or online.6   
The mechanisms by which dietary flaxseed may help to lower blood pressure are 
not well established. The research to date suggests that ALA and other fatty acids may 
have the ability to interfere with pro-inflammatory and pro-aggregatory eicosanoids. For 
example, both ALA and linoleic acid (LA) are essential fatty acids that can be converted 
to different fatty acids, which yield different classes of the eicosanoids. Eicosanoids are 
signaling molecules that exert control over many bodily functions. LA can be converted 
to arachidonic acid (AA) via the COX pathway. By the same method, ALA can be 
converted to eicosapaenoic acid (EPA) and, on a much smaller scale, docosahexaenoic 
acid (DHA).  These are the fatty acids primarily found in cold-water marine fish.7,8 AA is 
a precursor for the powerful vasoconstrictor and platelet agonist thromboxane (TXA2), 
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whereas, COX metabolism of EPA produces TXA3, which is relatively inactive.9 The 
theory is that these two fatty acids are in competition because they utilize the same 
enzymatic pathways. Therefore, an excess of one can lead to the production of specific 
eicosanoids.7,8 Another possible mechanism in which flax may affect blood pressure is 
the presence of gamma-tocopherol, a form of Vitamin E. It is an antioxidant that 
promotes sodium excretion in the urine and therefore may help lower blood pressure. 
This has not been thoroughly researched.6  
 There have been many studies demonstrating the antihypertensive properties of 
ALA in animals,10,11,12 but not many specifically geared toward the antihypertensive 
effects of dietary flaxseed in humans. This review will focus on the antihypertensive 
effect of dietary flaxseed in humans. 
METHODS 
An exhaustive search was performed in OVID using the terms flax, linseed oil, or 
flaxseed and blood pressure or hypertension. Similar search strategy was utilized in 
CINAHL and Web of Knowledge. Eligibility criteria included articles written in the 
English-language, human studies, and randomized-controlled trials (RCT). Exclusion 
criteria were any articles written before the year 2005 and any studies that were not 
specific to dietary flaxseed.  Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE)13 was utilized to assess the quality of relevant articles.  The 
National Institute of Health (NIH) clinical trials website was reviewed and found to have 
one registered trial14 assessing the efficacy of dietary flaxseed in reducing blood pressure 
in newly diagnosed hypertensive individuals. This study is still in developmental stages 
and is not yet recruiting any study participants.  
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RESULTS 
The original search using the method described above generated 42 articles.  After 
limitations were applied a total of 11 articles resulted. Of those 11 articles, two met the 
inclusion and exclusion criteria (See Table II).15,16  
 The FLAX-PAD study15 was a double blind, placebo controlled RCT utilized to 
examine the effects of dietary flaxseed on systolic and diastolic blood pressure in patients 
newly diagnosed with PAD.  Total length of the study was for 1 year, but the data 
analyzed was only up to 6 months. Inclusion criteria were patients over 40 years old who 
have had PAD for greater than 6 months with an Ankle Brachial Index (ABI) less than 
0.9. Exclusion criteria included inability to walk, bowel disease, moderate to severe renal 
failure, life expectancy of less than 2 years with high baseline cardiac risk, allergies to 
any ingredient used in the study, patients who plan to undergo surgery during the trial, 
and no more than two meals of fish per week.15   
A total of 110 patients were selected for this study. After randomization, patients 
were allocated to a treatment group and placebo. Patients in the treatment group (n=58) 
received 30g per day of milled flaxseed via several different foods.  The patients in the 
placebo group (n=52) received the same foods with no flaxseed. The intervention lasted 
for 6 months. Care was taken to conceal the ingredients of the foods ingested. Overall, 13 
patients from the flaxseed group and 11 patients from the placebo group were lost to 
follow-up.15  
Baseline characteristics, such as, age, cardiovascular (CV) risk factors, treatments 
for various CV risk factors, serum lipid levels, body mass index (BMI), and BP were 
measured. Plasma levels of ALA were measured at baseline. Although there were no 
 - 11 - Revised 07Dec2009 
significant differences between the treatment group and placebo in regards to baseline 
BMI, BP, and serum ALA, other baseline characteristics were prognostically worse in the 
treatment group. There were no significant differences between patients when examined 
as a function of the group to which they were allocated.  Some patients in both groups 
were taking diabetic medications, lipid-lowering agents, antithrombotic, or 
antihypertensive medications through the course of this study.15  
The primary end-point of this study was the ABI. Changes in SBP and DBP were 
designated as secondary end-points. Skilled nurses using a mercury sphygmomanometer 
in a controlled, quiet environment measured resting blood pressure. The average of three 
measurements was used. Plasma ALA, EPA, and DHA were measured as markers for 
dietary compliance. Body weight, waist circumference, and BMI were also measured.15  
ABI did not change significantly in the treatment group or the placebo group at 
baseline (0.80±0.24 versus 0.81±0.22; P=0.8) or during the intervention period 
(0.77±0.23 versus 0.78±0.22; P=0.8). BMI and waist circumference did not differ 
significantly between the two groups at any time during the trial. Body weights also 
showed no significant difference between the treatment and placebo groups at baseline 
(81.0±14.9 versus 82.4±14.8; P=0.6) or after six months (83.8±14.8 versus 
81.4±14.5; P=0.4).15  
Plasma levels of ALA, EPA, and DHA were similar at baseline in both groups.  
There were no significant increases in any of the plasma levels of fatty acids in the 
placebo group at any point during the study. On the contrary, ALA plasma levels 
increased two-fold in the flaxseed fed groups when measured at 1 and 6 months (P=0.003 
versus placebo).  There was also a significant increase in EPA levels in the flaxseed 
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group compared with placebo. DHA levels in the flaxseed group did not change during 
the study, suggesting that subjects did not consume fish during meals. The study also 
assessed the relationship between plasma ALA levels and SBP (P<0.04) and DBP 
(P<0.01) to find there was a significant correlation.15 
Both SBP and DBP decreased in the flaxseed group over the course of the study. 
SBP dropped to 136±22 mmHg (P=0.04) at 6 months in the flaxseed group. DBP also fell 
in the flaxseed group at 6 months to 71±11 mmHg (P=0.004). A subgroup analysis was 
completed with patients in the trial with a SBP of  >140. The study found patients who 
received flaxseed achieved a larger reduction in SBP (15mm Hg) and DBP (7mm Hg) 
after 6 months of intervention. The placebo group showed no significant difference in 
SBP or DBP during the same period.15  
In summary, researchers found the most important finding in the FLAX-PAD 
study was the antihypertensive effect shown by patients who ingested dietary flaxseed. 
These effects were demonstrated even in patients already taking antihypertensive 
medications, therefore, representing an effective combination of pharmacologic and non- 
pharmacologic therapies on lowering blood pressure. The authors also imply that the 
results from the study suggest severely hypertensive patients benefit the most from 
dietary flaxseed. Further trials will be needed to clearly show the antihypertensive effect 
of flaxseed as an independent factor.15  
Pachos et al16 was a prospective, two-group, parallel-arm design RCT to examine 
the effects of dietary flaxseed on blood pressure in middle-aged dyslipidemic men. 
Inclusion criteria were total cholesterol of higher than 200mg/dl and/or HDL cholesterol 
level lower than 40mg/dl. Exclusion criteria consisted of individuals with evidence of 
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infection or coexisting diabetes mellitus or renal, liver, or inflammatory disease. Subjects 
taking lipid-lowering or antihypertensive medications, consuming more than 30 U of 
alcohol per week, smoking more than two packs of cigarettes per day, or exercising more 
than 6 hours per week were also excluded. None of the participants were taking other 
forms of dietary supplements, such as fish oil, during the intervention period.16  
A total of 87 patients were recruited from the Department of Cardiology of Laiko 
Hospital, Athens, Greece, after history and physical examination, ECG, and laboratory 
analysis. All of the participants were males aged 35 to 70, who were first diagnosed with 
dyslipidemia without evidence of CHD. The subjects were randomly assigned in to two 
groups using a 2:1 process. The treatment group (n=59) received 15mL of flaxseed oil 
per day containing 8g of ALA and the placebo group (n=28) received 15ml of safflower 
oil per day containing 11g of LA. The intervention period lasted for 12 weeks. Allocation 
concealment was not specified and there were no losses to follow-up during the study.16 
Baseline characteristic, such as, age, height, weight, and BMI were not 
significantly different between groups. BMI did not change in either group over the 
course of the study (P>0.05). Baseline blood pressure was measured in the two groups 
and there were no significant differences found. There were no significant differences 
between the two groups in regards to diet and smoking habits (all P>0.05) at baseline or 
during the intervention period. Energy and macronutrient intake, as well as intake of 
individual n-3 polyunsaturated fatty acids (PUFA), were not significantly different 
between both groups.16  
The primary end points used in this study were SBP, DBP, and mean arterial 
pressure (MAP). Blood pressure was measured using a manual sphygmomanometer by a 
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single physician who was blinded as to which group individuals were allocated. The 
patients were seated and resting for at least 15 minutes at the time of measurement. 
Appropriate blood pressure monitoring standards were enforced and an average of three 
measurements from the right-arm were recorded. Dietary habits, alcohol consumption, 
and physical activity of each subject were monitored by weekly phone calls and monthly 
hospital visits. Collecting one 3-day dietary record during each monthly visit assessed 
dietary compliance. Dietary assessment was performed at entry to confirm that all 
patients were eating the average Greek diet.16  
After dietary supplementation was initiated, SBP, DBP, and MAP were all 
significantly lower (See Table III) in the flaxseed group when compared to the safflower 
group (P< 0.001). Group analysis revealed that dietary supplementation in the placebo 
group had no significant effect on blood pressure (all P>0.05). In contrast, the flaxseed 
group exhibited a decrease in SBP, DBP, and MAP compared to baseline (P<0.001).16  
Researches in this study concluded that dietary supplementation with flaxseed oil 
containing 8g/day for a 12-week period lowers both SBP and DBP in dsylipidemic men. 
They suggest the magnitude of the hypotensive effect (5mm Hg or 3-6%) is clinically 
relevant and expected to reduce the overall cardiovascular disease risks in these patients. 
Future studies will be needed to determine the underlying mechanism through which 
dietary ALA might lower blood pressure.16  
DISCUSSION 
 Up to 50g of ground, raw flaxseed per day has been shown to be safe and 
nutritionally beneficial in humans.22 These recent RCTs15,16 indicate the use of dietary 
flax supplementation may have a blood pressure lowering effect in selective patients, but 
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further research is still needed. In the FLAX-PAD trial,15 SBP and DBP were lower in the 
flax fed group when compared with placebo. Additionally, patients who entered the trial 
with a SBP >140 mm Hg obtained a significant reduction in both SBP and DBP from 
flaxseed consumption. The FLAX-PAD study15 further exhibited the correlation between 
circulating ALA levels and decreases in SBP and DBP, as well as enterolignan levels and 
decreases in DBP. In the Pachos et al16 article, another RCT, found that dietary 
supplementation with flax oil containing 8g/day of ALA for 12 weeks lowered both SBP 
and DBP in dyslipidemic men. These findings are clinically significant because they were 
both blinded, randomized, placebo controlled trials. In addition, the FLAX-PAD study15 
monitored dietary compliance by measuring serum ALA, EPA, and DHA levels. Both the 
flax and placebo group maintained the proper diet, as no inconsistencies were found. 
Effort was made in both studies15,16 to control for confounding factors and minimize their 
influence. Each study carefully selected its study population and monitored throughout 
the study with respect to their diet, physical activity, and smoking habits. 
 However, encouraging as these results are, they are not conclusive when 
compared to other studies. In one study,17 the effects of three diets supplemented with 
fish oil, safflower oil, and linseed oil on plasma lipoprotein concentration and blood 
pressure were examined. This study included thirty-nine normotensive and slightly 
hypercholesterolemic men. Researchers found that SBP fell by approximately 4% in the 
fish oil group and no significant changes in blood pressure were measured in the other 
two groups. Another observational study18 found conflicting evidence as well. This study 
examined the effects of short-term supplementation with dietary flaxseed on blood 
pressure and various other serum markers in healthy humans. Results from this study 
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showed that 4 weeks use of dietary flaxseed did not demonstrate a decrease in blood 
pressure.18 In addition, previous studies19,20 (although not specific to dietary flaxseed) 
failed to show a blood pressure lowering effect of ALA. In contrast, the results from a 
double blind, RCT21 of the effects flaxseed had on metabolic syndrome composite score 
demonstrated that men and women supplementing their diets with flaxseed lignan 
complex for six months lowered DBP. It is likely that these studies17,18,19,20 conflict with 
the evidence from the RCTs15,16 included in this review due to several factors. First, the 
observational study,18 which found against the antihypertensive effect of dietary flaxseed, 
may have been due to the type of study utilized. Second, it is also possible that results 
differ because some of the studies19,20 were not specific to dietary flaxseed, which 
suggests that there may be some additional components to flaxseed that might contribute 
to its antihypertensive effect. Lastly, it may also be suggested that dietary flaxseed 
intervention is more effective at lowering BP in patients who are already hypertensive, 
where subjects from both studies,17,18  were normotensive at baseline.  
 While these studies15,16 demonstrated the antihypertensive effects of dietary 
flaxseed, they both have some limitations that need to be addressed (See Table II).  In the 
FLAX-PAD trial,15 the presence of antihypertensive medications during the trial made it 
impossible to conclusively determine the effects of dietary flaxseed independently on 
blood pressure. This study also had a high attrition rate among both flaxseed and placebo 
groups. Although the losses were similar, this still may have affected the outcomes. In the 
Pachos et al study,16 several limitations were discussed. First, the parallel study design is 
not as strong as a crossover design. It was chosen because the washout period cannot be 
readily specified in a lipid intervention trial; thus avoiding any carryover effect that may 
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be caused by a crossover trial. Second, the dose of ALA is difficult to achieve by usual 
dietary intake. However, researchers suggested that certain food products might be 
infused with similar levels if not higher levels of ALA and are therefore attainable.16 
Lastly, this study16 utilized an imprecise method to report results due to the use of 
medians with 25th and 75th percentiles.  
CONCLUSION 
 Daily consumption of 30g of milled flaxseed or 15mL of flax oil per day has 
shown an antihypertensive effect on select patient populations. The latest studies 
regarding flaxseed and its antihypertensive effects seem promising, but further 
randomized controlled trials are needed to clearly establish its efficacy. Future studies 
should also be designed to identify the underlying mechanism by which ALA may reduce 
blood pressure, clearly identify the independent blood pressure lowering action of flax 
and show these effects on larger populations. Based on the GRADE criteria, the overall 
quality of the studies reviewed is moderate.  
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Table I. Nutritional Information of Flaxseed 
 
Flax Weight Energy 
kcal 
Total Fat ALA Protein Total 
Carbs 
Total 
Dietary 
Fiber 
Whole 
Seed 
180g        
(1 cup) 
810 74.0g 41.0g 36.0g 52.0g 50.0g 
 11g          
(1 tbsp) 
50 4.5g 2.5g 2.2g 3.0g 3.0g 
Milled 
Seed 
130g       
(1 cup) 
585 53.0g 30.0g 26.0g 38.g 36.0g 
 8g            
(1 tbsp) 
36 3.3g 1.8g 1.6g 2.3g 2.2g 
Flax Oil 100g 
 
884 100.0g 57.0g __ __ __ 
 14g 
(1tbsp) 
124 14g 8.0g __ __ __ 
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Table II. Characteristics of Reviewed Studies, GRADE 
Profile 
 
Quality Assessment 
Downgrade Criteria 
 Studies Design Limitations Indirectness Imprecision Inconsistency Publication 
bias likely 
Quality 
Lowering Blood Pressure 
FLAXPAD 
Study 
RCT Loss to 
follow-up 
over %20 
in both 
Flax and 
placebo 
groups 
No serious 
limitations 
No serious 
limitations 
No serious 
limitations 
No bias 
likely 
Moderate 
 
Pachos et 
al 
 
RCT 
 
No serious 
limitations 
 
No serious 
limitations 
 
Values are 
medians 
(25th to 75th 
percentile) 
 
No serious 
limitations 
 
No bias 
likely 
 
Moderate 
 
 
 
 
 
Table III. Blood Pressure Data Before and After Dietary 
Flaxseed Intervention 
 
LA group (n=28) ALA group (n=59) 
 Before After Change % Before After Change % P 
 
SBP 
(mmHg) 
 
122.5   
(120,140) 
 
127.5  
(118,132) 
 
-1.7 
 
120 
(110,130) 
 
110  
(108,124) 
 
-3.1 
 
0.016 
 
DBP 
(mmHg) 
 
80          
(75,85) 
 
79           
(75,85) 
 
-2.5 
 
80   
(75,88) 
 
72     
(65,80) 
 
-6.3 
 
0.011 
 
MAP 
(mmHg) 
 
94.2    
(90.2,104.6) 
 
95       
(88.7,100.8) 
 
-1.4 
 
93.3  
(86.7,98.3) 
 
85  
(78.3,98.3) 
 
-6.0 
 
0.010 
Values are medians (25th, 75th percentile) 
P-value indicates differences between LA and ALA groups, and has been derived from the analysis of variance for 
repeated measures. 
Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), linoleic acid (LA), alpha-
linolenic acid (ALA). 
